372 related articles for article (PubMed ID: 16420598)
1. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
Khan MA; Khan A; Owais M
FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice.
Khan MA; Nasti TH; Saima K; Mallick AI; Firoz A; Wajahul H; Ahmad N; Mohammad O
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):249-58. PubMed ID: 15196575
[TBL] [Abstract][Full Text] [Related]
3. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
González GM; Portillo OJ; Uscanga GI; Andrade SE; Robledo M; Rodríguez C; Elizondo M
J Antimicrob Chemother; 2009 Sep; 64(3):571-3. PubMed ID: 19570754
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis.
Ghannoum MA; Kim HG; Long L
J Antimicrob Chemother; 2007 Mar; 59(3):556-9. PubMed ID: 17242032
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
Khan MA; Nasti TH; Owais M
J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
[TBL] [Abstract][Full Text] [Related]
7. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
[TBL] [Abstract][Full Text] [Related]
8. Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis.
Wang Y; Jia XM; Jia JH; Li MB; Cao YY; Gao PH; Liao WQ; Cao YB; Jiang YY
Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):e40-6. PubMed ID: 19413603
[TBL] [Abstract][Full Text] [Related]
9. Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B.
Khan MA; Ahmad N; Moin S; Mannan A; Wajahul H; Pasha ST; Khan A; Owais M
FEMS Immunol Med Microbiol; 2005 Jun; 44(3):269-76. PubMed ID: 15907448
[TBL] [Abstract][Full Text] [Related]
10. Potential use of tuftsin in treatment of candida peritonitis in a murine model.
Levy R; Kain Z; Chaimovitz C; Fridkin M; Segal S; Alkan M
J Biol Regul Homeost Agents; 1989; 3(2):71-8. PubMed ID: 2554684
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole resistance in Candida albicans: a review of mechanisms.
Casalinuovo IA; Di Francesco P; Garaci E
Eur Rev Med Pharmacol Sci; 2004; 8(2):69-77. PubMed ID: 15267120
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis.
Masood AK; Faisal SM; Haque W; Owais M
J Drug Target; 2002 May; 10(3):185-92. PubMed ID: 12075819
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic role of immunomodulators in treatment of systemic candidiasis in leukopenic mice.
Khan MA; Firoz A; Jabeen R; Mohammad O
J Drug Target; 2004; 12(7):425-33. PubMed ID: 15621667
[TBL] [Abstract][Full Text] [Related]
14. Immune stimulating and therapeutic potential of tuftsin-incorporated nystatin liposomes against Cryptococcus neoformans in leukopenic BALB/C mice.
Khan MA; Aljarbou A; Khan A; Owais M
FEMS Immunol Med Microbiol; 2012 Oct; 66(1):88-97. PubMed ID: 22612788
[TBL] [Abstract][Full Text] [Related]
15. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B.
Khan MA; Syed FM; Nasti HT; Saima Dagger K; Haq W; Shehbaz A; Owais M
J Drug Target; 2003 Feb; 11(2):93-9. PubMed ID: 12881195
[TBL] [Abstract][Full Text] [Related]
16. Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.
Costa-de-Oliveira S; Miranda IM; Silva-Dias A; Silva AP; Rodrigues AG; Pina-Vaz C
Antimicrob Agents Chemother; 2015 Jul; 59(7):4289-92. PubMed ID: 25845879
[TBL] [Abstract][Full Text] [Related]
17. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Rautemaa R; Richardson M; Pfaller M; Koukila-Kähkölä P; Perheentupa J; Saxén H
J Antimicrob Chemother; 2007 Oct; 60(4):889-92. PubMed ID: 17704513
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis.
Lee JH; Jang EC; Han Y
Arch Pharm Res; 2011 Mar; 34(3):399-405. PubMed ID: 21547671
[TBL] [Abstract][Full Text] [Related]
20. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis.
Mencacci A; Cenci E; Bacci A; Bistoni F; Romani L
J Infect Dis; 2000 Feb; 181(2):686-94. PubMed ID: 10669356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
